

2.4.6 LIST OF LITERATURE REFERENCES

- [1] Abdel-Nabi H, Waldman WJ, Hinkle G, et al. Comparison of L-thyroxine and a saturated solution of potassium iodide in preventing damage to the thyroid following iodide-131-labeled antibody injection. NCI Monogr 1987; 3:63-6.
- [2] Actavis-UK. Summary of Product Characteristics: Levothyroxine tablets BP 50 micrograms [Internet]. Barnstaple (UK): Actavis UK Limited; 2014 Jul 21 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=23994>
- [3] AHFS (American Hospital Formulary Service) - Drug information. Levothyroxine sodium / Thyroid agents general statement [Internet]. Stuttgart (DE): Wissenschaftliche Verlagsgesellschaft; 2017 [cited 2017 Aug 09]. Available from: <http://www.drugbase.de>
- [4] Ananthakrishnan S, Braverman LE, Levin RM, et al. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid 2008; 18(5):493-8.
- [5] Aristo Pharma-DE. Fachinformation (SPC): Eferox® Lösung zum Einnehmen [Internet]. Berlin (DE): Aristo Pharma GmbH; April 2016 [cited 2017 Aug 01]. Available from: <http://fachinformation.srz.de/pdf/aristo/eferoxI%C3%B6sung.pdf>
- [6] Basso A, Mocchegiani E, Fabris N. Increased immunological efficiency in young mice by short-term treatment with L-thyroxine. J Endocrinol Invest 1981; 4(4):431-8.
- [7] BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte). Fixe AM-Kombination von Levothyroxin und Liothyronin (Tabletten 25 µg + 5 µg / 100 µg + 20 µg). Mustertext zur Fachinformation fi3800ap (levothyroxin+_oral_spcde_1999-05-20_004). Date: 20 May 1999.
- [8] BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte). Levothyroxin-Natrium. Mustertexte zur Fachinformation levothyroxin_oral_spcde_2002-11-05_003 und zur Gebrauchsinformation levothyroxin_oral_pal_2002-11-05_004. Date: 05 Nov 2002.
- [9] BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte). Public assessment report: Tirosint 13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 micrograms soft capsules. Levothyroxine sodium. Procedure number DE/H/2580/01-12/DC [Internet]. Loerrach (DE): Regiomedica GmbH; 2011 Mar 20 [cited 2017 Aug 01]. Available from: https://mri.cts-mrp.eu/Human/Downloads/DE_H_2580_012_PAR.pdf
- [10] BfArM-AMIS (Bundesinstitut fuer Arzneimittel und Medizinprodukte, Arzneimittelinformationssystem). Tirosint Weichkapseln (registered preparations in Germany) [Internet]. 01.08.2017a [cited 2017 Aug 02]. Available from: https://portal.dimdi.de/websearch/servlet/FlowController/AcceptFZK#_DEFANCHOR__
- [11] BfArM-AMIS (Bundesinstitut fuer Arzneimittel und Medizinprodukte, Arzneimittelinformationssystem). (((Stoffname: (LEVOTHYROXIN?; LEVOTHYROXIN-NATRIUM?) UND Arzneilich wirksame Bestandteile)/SAME STF) UND Anzahl Wirkstoffe: 01) UND Nur verkehrsfähige Arzneimittel UND Nur Humanarzneimittel (registered preparations in Germany) [Internet]. 11.10.2017b [cited 2017 Oct 11]. Available from: https://portal.dimdi.de/websearch/servlet/FlowController/AcceptFZK#_DEFANCHOR__
- [12] BGP Pharma-CA. Product Monograph: Synthroid® levothyroxine sodium tablets, USP 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg (Submission Control No: 181937). Montreal (CA): BGP Pharma ULC; 2015 Aug 20.
- [13] Bogazzi F, Bartalena L, Brogioni S, et al. L-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRβ. Mol Cell Endocrinol 1997; 134(1):23-31.
- [14] Briet JM, Van Wassenaer AG, Van Baar A, et al. Evaluation of the effect of thyroxine supplementation on behavioural outcome in very preterm infants. Dev Med Child Neurol 1999; 41(2):87-93.

2.4 Nonclinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

- [15] Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation - A reference guide to fetal and neonatal risk. Levothyroxine. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2011. p. 829-31.
- [16] Burger, AG. Neue Aspekte der peripheren Wirkung der Schilddrüsenhormone. Triangel 1983; 22: 175-9.
- [17] CBG-MEB (College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board, Netherlands). Eltroxin, Euthyrox. Database human medicines. Available from: http://www.cbg-meb.nl/CBG/en/_search/searchresult/default.htm?qry=euthyrox&language=en; downloaded October 10 2017.
- [18] Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006; 354:1787-95.
- [19] Chelimsky G, Davis ID, Kliegman RM. Neonatal hyponatremia associated with congenital hypothyroidism. Clin Pediatr (Phila) 1997; 36(3):177-80.
- [20] Cholongitas E, Georgousaki C, Spyrou S, et al. Stevens-Johnson syndrome related to ciprofloxacin, possibly enhanced by overadministration of levothyroxine. Dermatol Online J 2009; 15(11):16.
- [21] Colonis Pharma-UK. Summary of Product Characteristics: Levothyroxine 25 micrograms/5ml oral solution [Internet]. Burnopfield (UK): Colonis Pharma Ltd; 2017 May 13 [cited 2017 Aug 01]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=33293>
- [22] Connelly TJ, El-Hayek R, Sukhareva M, et al. L-thyroxine activates the intracellular Ca²⁺ release channel of skeletal muscle sarcoplasmic reticulum. Biochem Mol Biol Int 1994; 32(3):441-8.
- [23] Cooper JG, Harboe K, Frost SK, et al. Ciprofloxacin interacts with thyroid replacement therapy. BMJ 2005; 330(7498):1002.
- [24] CVMP (Committee for Veterinary Medicinal Products). Summary report: Levothyroxine (EMEA/MRL/319/97-FINAL) [Internet]. London: The European Agency for the Evaluation of Medicinal Products - Veterinary Medicines Evaluation Unit; 1998 June. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014686.pdf
- [25] De Launoit Y, Kiss R. Influence of L-thyroxine, L-triiodothyronine, thyroid stimulating hormone, or estradiol on the cell kinetics of cultured mammary cancer cells. In Vitro Cell Dev Biol 1989; 25(7):585-91.
- [26] Di Fulvio M, Coleoni AH, Pellizas CG, et al. Tri-iodothyronine induces proliferation in cultured bovine thyroid cells: evidence for the involvement of epidermal growth factor-associated tyrosine kinase activity. J Endocrinol 2000; 166(1):173-82.
- [27] Dietrich JW, Gieselbrecht K, Holl RW, et al. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res 2006; 38(1):57-9.
- [28] Drugs.com. Monograph: Levothyroxine [Internet]. Auckland (NZ): Drugsite Trust; 2017a [cited 2017 Aug 09]. Available from: <https://www.drugs.com/pro/levothyroxine.html>
- [29] Drugs.com. Monograph: Levothyroxine sodium [Internet]. Auckland (NZ): Drugsite Trust; 2017b [cited 2017 Aug 09]. Available from: <https://www.drugs.com/monograph/levothyroxine-sodium.html>
- [30] Egashira T, Yamanaka Y. Changes in MAO activities in several organs of rats after administration of l-thyroxine. Jpn J Pharmacol 1987; 45(2):135-42.
- [31] EMA (European Medicines Agency). Assessment report for Levothyroxine Alapis and associated names and Annex II. Scientific conclusions and grounds for refusal Procedure no.: EMEA/H/A-29/1328 (EMA/701628/2012) [Internet]. London (UK): European Medicines Agency (EMA); 14 Jan 2013a. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Levothyroxine_Alapis_29_4/WC500138883.pdf

2.4 Nonclinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

- [32] EMA (European Medicines Agency). List of Union reference dates and frequency of submission of periodic safety update reports (PSURs). EMA/630645/2012 Rev.12. Patient Health Protection. [Internet]. London (UK): European Medicines Agency (EMA); 31 Oct 2013b.
- [33] EMA (European Medicines Agency). Alli. Procedural steps taken and scientific information after the authorisation [Internet]. London (UK): European Medicines Agency (EMA); 2017 [cited 2017 Sep 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000854/WC500024119.pdf
- [34] Escriva F, Pascual-Leone AM, Galan A, et al. Circulating glucose, insulin and ketone bodies and enzymes of ketone body utilization in brain mitochondria from suckling rats treated with high L-thyroxine doses. *Rev Esp Fisiol* 1983; 39(4):363-71.
- [35] Eur. Ph. (European Pharmacopoeia) - European Pharmacopoeia 9th Edition (9.3) Online version 01/2018; incl. Arzneibuch-Kommentar (56. Aktualisierungslieferung 2017). Monograph: Levothyroxine sodium [CD-ROM]. Stuttgart / Eschborn: Wissenschaftliche Verlagsgesellschaft / Govi-Verlag - Pharmazeutischer Verlag GmbH; Strasbourg: Council of Europe; 2017.
- [36] Franklyn JA. Hypothyroidism. *Med Int* 1993; 5:161-4.
- [37] Garwood CL, Van Schepen KA, McDonough RP, et al. Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. *Pharmacotherapy* 2006; 26(6):881-5.
- [38] Gay RG, Graham S, Aguirre M, et al. Effects of 10- to 12-day treatment with L-thyroxine in rats with myocardial infarction. *Am J Physiol* 1988; 255(4 Pt 2):H801-6.
- [39] Greco DS, Rosychuk RA, Ogilvie GK, et al. The effect of levothyroxine treatment on resting energy expenditure of hypothyroid dogs. *J Vet Intern Med* 1998; 12(1):7-10.
- [40] Hansen SR, Timmons SP, Dorman DC. Acute overdose of levothyroxine in a dog. *J Am Vet Med Assoc* 1992; 200(10):1512-4.
- [41] Hernandez A, Obregon MJ. Triiodothyronine amplifies the adrenergic stimulation of uncoupling protein expression in rat brown adipocytes. *Am J Physiol Endocrinol Metab* 2000; 278(5):E769-77.
- [42] Hoeffken BR, Koedding R, Hehrmann R, et al. Further results on the subcellular conversion of T₄ to T₃ and rT₃. In: Von zur Muehlen A, Schleusener H, editors. Biochemical basis of thyroid stimulation and thyroid hormone action. Workshop Conference September 1975, Celle. Stuttgart (DE): Georg Thieme Publishers; 1976. p. 204-14.
- [43] IBSA-IT. Fachinformation (SPC): Tirosint 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg Weichkapseln. Lodi (IT): IBSA Farmaceutici Italia Srl; 2012 Jan [cited 2017 Aug 01].
- [44] Iishi H, Tatsuta M, Baba M, et al. Enhancement by thyroxine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. *Br J Cancer* 1993; 68(3):515-8.
- [45] Imada M, Kurosumi M, Fujita H. Three-dimensional imaging of blood vessels in thyroids from normal and levothyroxine sodium-treated rats. *Arch Histol Jpn* 1986; 49(3):359-67.
- [46] Jaggy A, Glaus T Jr, Tipold A. Neurologische Ausfallserscheinungen im Zusammenhang mit Hypothyreose beim Hund: Literaturuebersicht und Fallbeschreibungen. *Schweiz Arch Tierheilkd* 1994; 136(8):257-64.
- [47] Jauk B, Mikosch P, Gallowitsch HJ, et al. Unusual malabsorption of levothyroxine. *Thyroid* 2000; 10(1):93-5.
- [48] John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. *Thyroid* 2007; 17(8):763-5.
- [49] Jolin T, Herrera E. Effects of streptozotocin-diabetes and L-thyroxine treatment on plasma amino acid levels in thyroidectomized rats. *Horm Metab Res* 1982; 14(8):398-404.

2.4 Nonclinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

- [50] Jungermann K, Moehler H, editors. Biochemie - Ein Lehrbuch fuer Studierende der Medizin, Biologie und Pharmazie. Thyroxin. Berlin (DE): Springer-Verlag; 1980. p. 566-8.
- [51] Kaptein EM, Moore GE, Ferguson DC, et al. Thyroxine and triiodothyronine distribution and metabolism in thyroxine-replaced athyreotic dogs and normal humans. *Am J Physiol* 1993; 264(1 Pt 1):E90-100.
- [52] Kisch E, Segall HS. Interaction between simvastatin and L-thyroxine. *Ann Intern Med* 2005; 143(7):547.
- [53] Koehrlé J. Biochemistry of Iodothyronine deiodination. *Acta Austriaca* (Special edition) 1988; 15:22-4.
- [54] Kueemmerle HP, Hitzemberger G, Spitzky KH, editors. Klinische Pharmakologie. Levo-Thyroxin-Natrium, T4 / Liothyronin, T3. 4.Aufl./53. Erg.-Lfg. 11/1997. Landsberg/Muenchen (DE): Ecomed Verlagsgesellschaft; 1984; inkl. 53. Erg.-Lfg. 1997.
- [55] Lazarus JH. Thyroid hormone and intellectual development: a clinician's view. *Thyroid* 1999; 9(7):659-60.
- [56] Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. *J Clin Endocrinol Metab* 1996; 81(2):857-9.
- [57] Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. *Br J Clin Pharmacol* 2005; 60(3):337-41.
- [58] Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. *Best Pract Res Clin Endocrinol Metab* 2009; 23(6):781-92.
- [59] Lomo PO, Makawiti DW, Konji VN. The effect of L-thyroxine on the anaemia response in *Trypanosoma congolense* infected rabbits. *Vet Parasitol* 1995; 58(3):227-34.
- [60] Maeda N, Amano H, Machino M, et al. L-thyroxine, cortisol, and diet affect the postnatal development of the facial part of the skull in developing rats. *Anat Anz* (Jena) 1986; 161(2):99-104.
- [61] Martindale - The Complete Drug Reference. Levothyroxine sodium / Thyroid and antithyroid drugs [Internet]. London (UK): Pharmaceutical Press; 2017 [cited 2017 Aug 09]. Available from: <https://www.medicinescomplete.com>
- [62] Meng W, editor. Schildruesenerkrankungen. Anatomie und Physiologie. 3rd ed. Jena (DE): Gustav Fischer Verlag; 1992. p. 18-26.
- [63] Merck Index – The Merck Index. Thyroxine [CD-ROM]. 14th ed. Whitehouse Station (NJ): Merck & Co., Inc. 2006 [cited 2017 Sep 20].
- [64] Mercury-UK. Summary of Product Characteristics: Eltroxin 50 micrograms per 5 ml oral solution [Internet]. London (UK): Mercury Pharmaceuticals Ltd.; 2013 Aug 30 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=26563>
- [65] Mercury-UK. Summary of Product Characteristics: Levothyroxine 100micrograms per 5ml Oral Solution [Internet]. London (UK): Mercury Pharmaceuticals Ltd; 2015 May 15 [cited 2017 Aug 01]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=28153>
- [66] Mercury-UK. Summary of Product Characteristics: Eltroxin 100mcg tablets [Internet]. London (UK): Mercury Pharmaceuticals Ltd; 2016 Apr 20 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=23699>
- [67] Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. *Pharmacol Toxicol* 1999; 84(3):107-9.

2.4 Nonclinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

- [68] MHRA (Medicines and Healthcare products Regulatory Agency). UK Public Assessment Report: Evotrox 25 mcg, 50 mcg, 100 mcg/5ml oral solution (PL 20249/0004, PL 20249/0007, PL 20249/0005) [Internet]. Wembley (UK): Kappin Limited; 23 Jan 2013a. Available from: <http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2024367.pdf>
- [69] MHRA (Medicines and Healthcare products Regulatory Agency). Levothyroxine tablet products: a review of clinical & quality considerations [Internet]. London (UK): Medicines and Healthcare Products Regulatory Agency (MHRA); 07 Jan 2013b. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420997/CHM_Review_for_MHRA_website_Levothyroxine_sodium_FINAL_04_Jan_2013.pdf
- [70] Moericke R, Tittbach O, Kellner K, et al. Der Einfluß der noradrenergen Stimulation auf die peripheren venösen Thyroxin- und Liothyroninkonzentrationen stoffwechselgesunder jugendlicher Probanden. *Z Gesamte Inn Med* 1980; 35(10):433-9.
- [71] Morin PP, Winberg S, Nilsson GE, et al. Effects of L-thyroxine on brain monoamines during parr-smolt transformation of Atlantic salmon (*Salmo salar* L.). *Neurosci Lett* 1997; 224(3):216-8.
- [72] Mutapcic L, Wren SM, Leske DA, et al. The effect of L-thyroxine supplementation on retinal vascular development in neonatal rats. *Curr Eye Res* 2005; 30(12):1035-40.
- [73] Nachreiner RF, Refsal KR, Ravis WR, et al. Pharmacokinetics of L-thyroxine after its oral administration in dogs. *Am J Vet Res* 1993; 54(12):2091-8.
- [74] Nolan SR, Self TH, Norwood JM. Interaction between rifampin and levothyroxine. *South Med J* 1999; 92(5):529-31.
- [75] Oerbeck B, Reinvang I, Sundet K, et al. Young adults with severe congenital hypothyroidism: cognitive event related potentials (ERPs) and the significance of an early start of thyroxine treatment. *Scand J Psychol* 2007; 48(1):61-7.
- [76] Ogilvy-Stuart AL. Neonatal thyroid disorders. *Arch Dis Child Fetal Neonatal Ed* 2002; 87(3):F165-71.
- [77] Ongphiphadhanakul B, Alex S, Braverman LE, et al. Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin. *J Bone Miner Res* 1992; 7(10):1227-31.
- [78] Osborn DA. Thyroid hormones for preventing neurodevelopmental impairment in preterm infants (Cochrane review). In: *The Cochrane Library*, Issue 2, 2003. Oxford Update Software.
- [79] Panciera DL, Atkins CE, Bosu WT, et al. Quantitative morphologic study of the pituitary and thyroid glands of dogs administered L-thyroxine. *Am J Vet Res* 1990; 51(1):27-31.
- [80] Panciera DL, Keene BW, Mier HC. Administration of levothyroxine to euthyroid dogs does not affect echocardiographic and electrocardiographic measurements. *Res Vet Sci* 1992; 53(1):130-2.
- [81] Panciera DL. An echocardiographic and electrocardiographic study of cardiovascular function in hypothyroid dogs. *J Am Vet Med Assoc* 1994; 205(7):996-1000.
- [82] Panza N, Biondi B, Carella C, et al. About thyroxine administration during lithium therapy. *J Endocrinol Invest* 1999; 22(10):820-1.
- [83] PDR (Physicians' Desk Reference). Levoxyl (levothyroxine sodium) [Internet]. 2017a [cited 2017 Sep 20]. Available from: <http://www.pdr.net/drug-summary/Levoxyl-levothyroxine-sodium-2553.73>
- [84] PDR (Physicians' Desk Reference). Synthroid® (levothyroxine sodium tablets, USP) [Internet]. 2017b [cited 2017 Sep 20]. Available from: <http://www.pdr.net/drug-information/synthroid?druglabelid=26>
- [85] PDWS. Rapporteur's public assessment report for paediatric studies submitted in accordance with article 45 of regulation (EC) No1901/2006, as amended. Levothyroxine (l-thyroxine) SE/W/004/pdWS/001. 2010 Apr 23.

2.4 Nonclinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

- [86] Pfannenstiel P, Saller B. Schilddruesenkrankheiten - Diagnose und Therapie. 2nd ed. Henning Berlin, editor. Berlin (DE): Berliner Medizinische Verlagsanstalt GmbH; 1991. p. 28-33.
- [87] Pincus D, Gomes T, Hellings C, et al. A population-based assessment of the drug interaction between levothyroxine and warfarin. *Clin Pharmacol Ther* 2012; 92(6):766-70.
- [88] Porterfield SP. Prenatal exposure of the fetal rat to excessive L-thyroxine or 3,5-dimethyl-3'-isopropyl-thyronine produces persistent changes in the thyroid control system. *Horm Metab Res* 1985; 17(12):655-9.
- [89] ratiopharm-DE. Fachinformation (SPC): Levothyroxin-ratiopharm 25, 50, 100 Mikrogramm/5 ml Loesung zum Einnehmen [Internet]. Ulm (DE): ratiopharm GmbH; 2017 May [cited 2017 Aug 01]. Available from: <https://portal.dimdi.de/amispb/doc/2017/06/16/2183359/O1d18e95c22144b298805109f046fd2c8.pdf>
- [90] Reddy SS. Endocrinology update 2006. *Cleveland Clin J Med* 2006; 73(11):1019-24.
- [91] Reinhardt W, Paul TL, Allen EM, et al. Effect of L-thyroxine administration on the incidence of iodine induced and spontaneous lymphocytic thyroiditis in the BB/Wor rat. *Endocrinology* 1988; 122(3):1179-81.
- [92] Rossoff IS, editor. Encyclopedia of clinical toxicology - Thyroxine. Boca Raton (FL): The Parthenon Publishing Group; 2002. p. 1063-4.
- [93] RTECS (Registry of Toxic Effects of Chemical Substances). Levothyroxine (L-thyroxine, T4) / Levothyroxine sodium. STN Easy online-protocol, Sep 2017.
- [94] Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. *Endocr Pract* 2007; 13(4):345-9.
- [95] Schifferdecker E, Jungmann E, Ruemelin A, et al. Behandlung mit Dopamin - eine wichtige GroeÙe bei der Beurteilung der Schilddruesenfunktion kritisch Kranker. *Klin Wochenschr* 1985; 63 Suppl 4:71-2.
- [96] Schjeide OA, Prahlad KV, Molsen D, et al. Morphological and metabolic responses of embryonic hearts to administration of exogenous L-thyroxine. *Cytobios* 1989; 60(241):71-95.
- [97] Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. *JAMA* 1998; 279(10):750.
- [98] Scholle S, Braeunlich H. Effects of prenatally administered thyroid hormones or glucocorticoids on maturation of kidney function in newborn rats. *Dev Pharmacol Ther* 1989; 12(3):162-8.
- [99] Seidel CH, Sydow K, Ziegelitz D, et al. Schilddruesenhormone, Thyrotropin, TBG-Spiegel und Bindungskapazitaet. *Dtsch Gesundheitw* 1980; 35(12):460-6.
- [100] Serb-FR. L-thyroxine Serb 150 microgrammes/ml, solution buvable en gouttes [Internet]. Paris (FR): SERB; 2015 Jul 21 [cited 2017 Aug 29]. Available from: <http://www.medisite.fr/dictionnaire-des-medicaments-l-thyroxine-serb-150-microgrammesml-solution-buvable-en-gouttes.604850.8028.html>
- [101] Seymen O, Seven A, Candan G, et al. The effect of iron supplementation on GSH levels, GSH-Px, and SOD activities of erythrocytes in L-thyroxine administration. *Acta Med Okayama* 1997; 51(3):129-33.
- [102] Siegenthaler W, editor. Klinische Pathophysiologie (Schilddruese). 7th ed. Stuttgart (DE): Georg Thieme Verlag; 1994. p. 263-78.
- [103] Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. *JAMA* 2000; 283(21):2822-5.
- [104] Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. *Thyroid* 2001; 11(10):967-71.
- [105] Smit BJ, Kok JH, de Vries LS, et al. Somatosensory evoked potentials in very preterm infants in relation to L-thyroxine supplementation. *Pediatrics* 1998; 101(5):865-9.

2.4 Nonclinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

- [106] Stockigt JR. Thyroid disease. *Med J Aust* 1993; 158:770-4.
- [107] Suwanwalaikorn S, Ongphiphadhanakul B, Braverman LE, et al. Differential responses of femoral and vertebral bones to long-term excessive L-thyroxine administration in adult rats. *Eur J Endocrinol* 1996; 134(5):655-9.
- [108] Timmermans LP, Chmilevsky DA, Komen H, et al. Precocious onset of spermatogenesis in juvenile carp (*Cyprinus carpio* L., Teleostei) following treatment with low doses of L-thyroxine. *Eur J Morphol* 1997; 35(5):344-53.
- [109] Tomanek RJ, Connell PM, Butters CA, et al. Compensated coronary microvascular growth in senescent rats with thyroxine-induced cardiac hypertrophy. *Am J Physiol* 1995; 268(1 Pt 2):H419-25.
- [110] Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine. *AIDS* 1998; 12(16):2235-6.
- [111] Upadhyaya L, Agrawal JK, Dubey GP. Effect of L-thyroxine and carbimazole on blood levels of biogenic amines in rat. *Exp Clin Endocrinol* 1993; 101(5):307-10.
- [112] Verma P, Noble S, Miller R. Effect of L-thyroxine on serum angiotensin converting enzyme activity in sheep. *Clin Exp Pharmacol Physiol* 1986; 13(8):609-12.
- [113] Virili C, Trimboli P, Romanelli F, et al. Liquid and softgel levothyroxine use in clinical practice: state of the art. *Endocrine* 2016; 54(1):3-14.
- [114] Wachtlova M, Ostadal B, Mares V. Thyroxine-induced cardiomegaly in rats of different age. *Physiol Bohemoslov* 1985; 34(5):385-94.
- [115] Wenzel KW, Kirschsieper HE. Untersuchungen zur Resorption von L-Thyroxin beim Gesunden. *Compart N Nucl Med* 1975; 2: 30-1.
- [116] WHO (World Health Organization). Model list of essential medicines [Internet]. Levothyroxine. 20th ed. Geneva (CH): WHO; March 2017a. [cited 2017 Aug 09]; p. 42. Available from: http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1
- [117] WHO (World Health Organization). WHO model list of essential medicines for children [Internet]. Levothyroxine. 6th list. Geneva (CH): WHO; March 2017b [cited 2017 Aug 09]. p. 31. Available from: http://www.who.int/medicines/publications/essentialmedicines/6th_EMLc2017.pdf?ua=1
- [118] Williams FL, Watson J, Ogston SA, et al. Maternal and umbilical cord levels of T4, FT4, TSH, TPOAb, and TgAb in term infants and neurodevelopmental outcome at 5.5 years. *J Clin Endocrinol Metab* 2013; 98(2):829-38.
- [119] Wockhardt-UK. Summary of Product Characteristics: Levothyroxine 50micrograms/5ml Oral Solution [Internet]. Wrexham (UK): Wockhardt UK Ltd; 2017 Jun 23 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=33388>
- [120] Woeber KA. Update on the management of hyperthyroidism and hypothyroidism. *Arch Fam Med* 2000; 9(8):743-7.
- [121] Wood RW, Martis L, Gillum AW, et al. In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. *J Pharm Sci* 1990; 79(2):124-7.
- [122] Yao J, Eghbali M. Decreased collagen mRNA and regression of cardiac fibrosis in the ventricular myocardium of the tight skin mouse following thyroid hormone treatment. *Cardiovasc Res* 1992; 26(6):603-7.
- [123] Yosha S, Longcope C, Braverman LE. The effect of D- and L-thyroxine on sex hormone-binding globulin in rabbits. *Endocrinology* 1984; 115(4):1446-50.
- [124] Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. *Thyroid* 2011; 21(5):483-6.
- [125] Zendzian-Piotrowska M, Gorska M, Dworakowski W, et al. Effect of triiodothyronine on phospholipid metabolism in skeletal muscles of the rat. *J Physiol Pharmacol* 2000; 51(1):103-10.